Royalty Pharma plc (RPRX) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
Royalty Pharma plc (RPRX) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current assets$1.76 BCurrent liabilities$630.93 MLiabilities$10.03 BAssets$19.82 BNon-current liabilities$9.40 BNon-current assets$18.06 BEquity$9.79 BGross equity(calculated)$9.79 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSFinancial royalty assetsCash and cash equivalentsOther royalty income receivableAvailable for sale debt securitiesOther current assetsFinancial royalty assets, netGoodwillAvailable for sale debt securitiesEquity method investmentsEquity securitiesOther assetsCurrent portion of long-term debtInterest payableDistributions payable to non-controlling interestsAccounts payable and accrued liabilitiesOther current liabilitiesLong-term debtAccrued compensation liabilitiesOther liabilitiesAdditional paid-in capitalRetained earningsCommon stock - Class R Redeemable SharesCommon stock - Class A Ordinary SharesNon-controlling interestsCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury interestsCurrent portion of long-term debtCurrent portion of long-term debt$380.00 MFinancial royalty assetsFinancial royalty assets$889.45 MInterest payableInterest payable$107.77 MCash and cash equivalentsCash and cash equivalents$811.99 MCurrent assetsCurrent assets$1.76 BCurrent liabilitiesCurrent liabilities$630.93 MDistributions payable to non-controlling interestsDistributions payable to non-controlling interests$91.28 MOther royalty income receivableOther royalty income receivable$31.47 MLiabilitiesLiabilities$10.03 BAccounts payable and accrued liabilitiesAccounts payable and accrued liabilities$35.57 MAvailable for sale debt securitiesAvailable for sale debt securities$25.00 MAssetsAssets$19.82 BOther current liabilitiesOther current liabilities$16.32 MOther current assetsOther current assets$6.66 MNon-current liabilitiesNon-current liabilities$9.40 BLong-term debtLong-term debt$8.58 BNon-current assetsNon-current assets$18.06 BFinancial royalty assets, netFinancial royalty assets, net$16.19 BAccrued compensation liabilitiesAccrued compensation liabilities$713.22 MEquityEquity$9.79 BOther liabilitiesOther liabilities$108.02 MGross equity (calculated)Gross equity(calculated)$9.79 BAdditional paid-in capitalAdditional paid-in capital$4.38 BGoodwillGoodwill$923.54 MRetained earningsRetained earnings$2.46 BAvailable for sale debt securitiesAvailable for sale debt securities$372.10 MCommon stock - Class R Redeemable SharesCommon stock - Class R Redeemable Shares$63.00 KEquity method investmentsEquity method investments$261.97 MCommon stock - Class A Ordinary SharesCommon stock - Class A Ordinary Shares$45.00 KEquity securitiesEquity securities$241.92 MNon-controlling interestsNon-controlling interests$2.95 BOther assetsOther assets$62.96 MTreasury interestsTreasury interests−$2.72 M
Chart details

Royalty Pharma plc (RPRX) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
19,819,771,000 US dollars
Current assets
1,764,570,000 US dollars
Non-current assets
18,055,201,000 US dollars
Liabilities
10,034,057,000 US dollars
Current liabilities
630,928,000 US dollars
Non-current liabilities
9,403,129,000 US dollars
Equity
9,785,714,000 US dollars
Noncontrolling interest
2,952,975,000 US dollars. Included in consolidated equity; this amount is not added again.
Financial royalty assets
889,454,000 US dollars
Cash and cash equivalents
811,986,000 US dollars
Other royalty income receivable
31,474,000 US dollars
Available for sale debt securities
25,000,000 US dollars
Other current assets
6,656,000 US dollars
Financial royalty assets, net
16,192,717,000 US dollars
Goodwill
923,535,000 US dollars
Available for sale debt securities
372,100,000 US dollars
Equity method investments
261,973,000 US dollars
Equity securities
241,918,000 US dollars
Other assets
62,958,000 US dollars
Current portion of long-term debt
380,000,000 US dollars
Interest payable
107,766,000 US dollars
Distributions payable to non-controlling interests
91,280,000 US dollars
Accounts payable and accrued liabilities
35,566,000 US dollars
Other current liabilities
16,316,000 US dollars
Long-term debt
8,581,892,000 US dollars
Accrued compensation liabilities
713,219,000 US dollars
Other liabilities
108,018,000 US dollars
Additional paid-in capital
4,376,266,000 US dollars
Retained earnings
2,459,089,000 US dollars
Common stock - Class R Redeemable Shares
63,000 US dollars
Common stock - Class A Ordinary Shares
45,000 US dollars
Deferred shares, $0.000001 par value; issued and outstanding: 2026–430,189 and 2025–411,475
0 US dollars
Common stock - Class B Ordinary Shares
0 US dollars
Non-controlling interests
2,952,975,000 US dollars
Treasury interests
negative 2,724,000 US dollars
Gross equity (calculated)
9,788,438,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
Royalty Pharma plc (RPRX) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!